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Effect of Human S100A13 Gene Silencing on FGF-1
Transportation in Human Endothelial Cells
Renxian Cao,1* Bin Yan,2 Huiling Yang,2 Xuyu Zu,2 Gebo Wen,1* Jing Zhong2
Background/Purpose: The S100 protein is part of a Ca2+ binding protein superfamily that contains an EF-
hand domain, which is involved in the onset and progression of many human diseases, especially the pro-
liferation and metastasis of tumors. S100A13, a new member of the S100 protein family, is a requisite
component of the fibroblast growth factor-1 (FGF-1) protein release complex, and is involved in human
tumorigenesis by interacting with FGF-1 and interleukin-1. In this study, experiments were designed to 
determine the direct role of S100A13 in FGF-1 protein release and transportation.
Methods: We successfully constructed the lentiviral vectors containing shRNA targeting the human
S100A13 gene. Human umbilical vein endothelial cells (HUVECs) were transfected with lentiviral RNAi
vectors for S100A13. Then immunofluorescence staining, real-time quantitative polymerase chain reac-
tion and Western blotting were used to detect the inhibition efficiency of the vectors and to monitor the
release and transportation of FGF-1 protein.
Results: Lentiviral RNAi vectors induced suppression efficiency of S100A13 gene by 90% in HUVECs. 
FGF-1 protein was found to be transported from the cytoplasm to the cell membrane, and then released
from cells when HUVECs were deprived of serum. The release of FGF-1 protein was blocked by the down-
regulation of S100A13, but the transportation was not affected, suggesting that S100A13 is a key cargo protein
for FGF-1 release.
Conclusion: S100A13 promotes the release of FGF-1 protein, but does not affect the transportation of
FGF-1 protein in HUVECs.
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The S100 protein family is a Ca2+ binding protein
superfamily. This family contains an EF-hand do-
main, which is involved in the onset and progres-
sion of a wide range of human diseases, such as
cholecystic fibrosis, cardiomyopathy, rheumatic
arthritis and tumorigenesis.1,2 So far, 25 mem-
bers of this family have been found in humans.3
S100A13, an acidic, 11-kDa protein, is the only
member of the S100 protein family that is widely
expressed in various tissues. Compared with other
S100 proteins, S100A13 has specific physical and
functional characteristics, including broad Ca2+
sensitivity, unusual metal-free state and the ab-
sence of a surface-exposed hydrophobic patch
when in the Ca2+-saturated state.4 Following anal-
ysis of differentially expressed genes, using sup-
pression subtractive hybridization, in normal
thyroid tissue and thyroid tumors, we found that
S100A13 was highly expressed in thyroid cancer.
We therefore constructed a S100A13 eukaryotic
expression vector to investigate the function of this
protein. Recently, S100A13 has attracted interest
for its involvement in non-classical pathway trans-
membrane transport of fibroblast growth factor-1
(FGF-1) and interleukin-1a, which are involved
in angiogenesis, tumor growth, and cell prolifer-
ation and differentiation.5,6
FGF-1 is a member of the fibroblast growth
factor family, which acts as a broad-spectrum mi-
togen and potent angiogenic agent.7,8 Thus, FGF-
1 appears to play a significant role, not only in
normal development and wound healing, but also
in tumor development and progression. FGF-1
has also evoked interest as a candidate oncogene
as it can potentially initiate and promote tumori-
genesis.7 These biological effects are mediated
through the activation of fibroblast growth factor
receptors (FGFRs), with the participation of he-
paran sulfate proteoglycans, and consequently
require the release of the polypeptide to produce
an action.9 However, FGF-1 lacks classical signal
peptide sequences at the N-terminal, and there-
fore cannot be secreted via the classical pathway
mediated by the endoplasmic reticulum-Golgi
complex; it is instead released by novel secretion
mechanisms. Some studies have suggested that
S100A13, p40Syt-1 and FGF-1 form the release
complexes to allow the transmembrane transport
of FGF-1 during its release.10,11 A detailed study of
the contribution that S100A13 has on the secretion
of FGF-1 is still required.
In this study, we successfully constructed a
shRNA lentiviral vector targeting the human
S100A13 gene using the Gateway technique. This
vector was used to investigate the role of S100A13
in the intracellular translocation and release of
FGF-1 induced by serum deprivation stress. These
studies were achieved through effective downreg-
ulation of the S100A13 gene in human umbilical
vein endothelial cells (HUVECs).
Materials and Methods
Cell line and reagents
HUVECs were cultured in high glucose DMEM
medium containing 10% fetal bovine serum in a
5% CO2 incubator at 37°C. BLOCK-iT™ Lentivi-
ral RNAi Expression System, SuperScript™III cDNA
reverse transcription kit and Trizol reagent were
purchased from the Invitrogen (Carlsbad, CA,
USA); the plasmid extraction kit was from Pro-
mega (Annadale, NSW, Australia); the BCA pro-
tein quantification kit was from KeyGEN Biology
Inc. (Nanjing, China); rabbit anti-human S100A13
antibody was a gift from Claus W. Heizmann;
rabbit anti-human β-actin polyclonal antibody,
goat anti-rabbit secondary antibody labeled with
CYC3 fluorescein and goat anti-rabbit secondary
antibody labeled with horseradish peroxidase
were purchased from Santa Cruz Inc. (Santa
Cruz, CA, USA); BlueRanger pre-stained protein
marker and fluorescence assay kit were from
Hyclone-Pierce (South Logan, UT, USA); Premix
Ex Taq kit was from Takara Bio Inc. (Otsu, Shiga,
Japan). DMEM medium and fetal bovine serum
were purchased respectively from Hyclone Com-
pany and Hangzhou Sijiqing Biological Engineer-
ing Materials Co. Ltd. (Qingtaimen, Hangzhou,
China). Taqman probes and primers for real-time
quantitative polymerase chain reaction (PCR) were
purchased from Takara Bio Inc.
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Generation of the S100A13 
shRNA-pENTR/U6 entry vector
We designed and synthesized two complementary
DNA oligonucleotides according to the nucleotide
sequence of S100A13 reported in GenBank (NM
001024210), and following the designing princi-
ples for shRNA given by Invitrogen. Top strand
oligo: 5’-CACCGGAAGATGTAATG CACCTTGAC-
GAATCAAGGTGC ATTACATCTTCC-3’; Bottom
strand oligo: 5’-AAAAGGAAGATGTAATGCACCT-
TGATTCGTCAAGGTGCATTACATCTTCC-3’. Top
and bottom strand oligos were annealed to gen-
erate double-stranded (ds) oligos. The ds oligo
was then cloned into the pENTR/U6 entry vector
by T4 DNA Ligase, and the resulting entry clone
contained the U6-S100A13 RNAi cassette (human
U6 promoter + ds oligo + PolIII terminator). The
pENTR/U6-S100A13 entry construct was verified
by DNA sequencing (Shanghai Sangon Biotech,
Shanghai, China).
Construction of the S100A13 pLenti6/
BLOCK-iT expression vector
With the catalysis of LR clonase II, the U6-S100A13
RNAi cassette in pENTR/U6 was transferred into
the pLenti6/BLOCK-iT-DEST Vector using the LR
recombination reaction to generate the pLenti6-
GW/U6-S100A13shRNA expression construct. The
pLenti6-GW/U6-S100A13shRNA expression con-
struct was identified by PCR.
Transfection of the lentiviral RNAi vectors 
for the S100A13 gene into HUVECs
One day before transfection, cells were plated in
growth medium without antibiotics at a density
allowing 50% confluence for the time of trans-
fection. RNAi vectors for S100A13 were transfected
into HUVECs according to the manufacturer’s
protocol for Lipofectamine 2000. Cells were har-
vested 72 hours later.
Real-time quantitative PCR analysis of
S100A13 gene expression
Total RNA was extracted with Trizol reagent from
four groups of cells: (1) the control cells, (2) SR-
PSOX lentiviral RNAi vector (generation in our
laboratory) transfected cells, (3) S100A13 lentiviral
RNAi entry vector transfected cells and (4) S100A13
lentiviral RNAi expression vector transfected cells.
cDNA was then synthesized from this RNA using
the SuperScriptIII cDNA reverse transcription kit.
Taqman probes and primers for the S100A13
and GAPDH genes were used. S100A13 Taqman
probe: 5’-CGCTGAGGCTATCCTTCCGGCC-3’; for-
ward primer: 5’-TTCTTCACCTTTGCAAGGC-3’, re-
verse primer: 5’-GAGAGCCCACATCCTTGAGC-3’.
GAPDH Taqman probe and primers were pur-
chased from Takara Inc. A total of 1 × 106 copies
of cDNA from normal HUVECs were diluted by
a factor of 10 and used to generate standard curves
of S100A13 and GAPDH genes. Real-time quan-
titative PCR reaction buffer was made using the
Premix Ex Taq kit.
Western blot analysis for S100A13 protein
expression
Total protein was extracted from cells in the four
groups (as listed above). Protein concentration
was determined using a BCA protein quantifica-
tion kit. After samples were boiled for 10 minutes,
proteins were subjected to SDS-PAGE, and then
transferred to PVDF membrane. The membrane
was blocked with TBST containing 5% skim milk
powder for 2 hours. Rabbit anti-human S100A13
antibody and rabbit anti-human β-actin antibody
at a concentration of 1:1000 and 1:400, respec-
tively, were used to probe the membrane, which
was incubated overnight at 4°C. The following
day, the membrane was exposed to goat anti-rabbit
secondary antibody labeled with horseradish per-
oxidase and incubated at 37°C for 45 minutes.
Bands were then visualized using a protein fluo-
rescence detection kit (Hyclone-Pierce).
Indirect immunofluorescence analysis
HUVECs were divided into four groups: (1) control
cells, (2) S100A13 RNAi cells, (3) HUVECs deprived
of serum for 3 hours and (4) S100A13 RNAi cells
deprived of serum for 3 hours. These four groups
and the four groups listed earlier were cultured in
12-well plates. The following day, cells were fixed
with methanol/glacial acetic acid (3:1 v/v) for 
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15 minutes, permeabilized with 0.25% Triton +5%
DMSO for 20 minutes, and blocked for 2 hours.
Cells were exposed to rabbit anti-human FGF-1 an-
tibody (1:100) and rabbit anti-human S100A13 an-
tibody (1:1000) primary antibodies and incubated
overnight at 4°C. The following day goat anti-
rabbit secondary antibody labeled with CYC3 fluo-
rescence (1:3000) was added to the cells, and
incubated for 45 minutes. The results were observed
and photographed using fluorescence microscopy.
Enzyme-linked Immunosorbent assay (ELISA)
Cells were divided into the four groups listed for
indirect immunofluorescence. A total of 1 × 105
cells/well were plated into a 12-well plate and
grown to 60–70% confluence within 24 hours.
Cell culture medium was collected and analyzed
according to the manufacturer’s instructions given
in the ELISA kit. To eliminate the effect of cell num-
ber on concentration of FGF-1 in the cell medium,
cells in each group were trypsinized, counted and
the ELISA value was corrected for cell density.
Co-immunoprecipitation
Cells were lysed in a buffer composed of 50 mM
Tris, pH 7.6, 150 mM sodium chloride, 1% non-
idet P-40, 10 mM sodium phosphate, 10 mM
sodium fluoride, 1 mM sodium orthovanadate,
2 mM phenylmethylsulfonyl fluoride, 10 μg/mL
aprotinin, 10 μg/mL leupeptin, and 10 μg/mL pep-
statin. After centrifugation, 50 μg of the clarified
cell lysate was incubated with 1 μg of FGF-1 anti-
body or 1 μg of S100A13 antibody at 4°C over-
night, followed by incubation with a slurry of
Sepharose protein A/G beads (40 μL) at 4°C for
1 hour with gentle shaking. Beads were collected
by brief centrifugation and washed five times with
lysis buffer. Proteins were eluted with 50 μL of
100 mM glycine (pH 2.5) and separated on an
8–12% SDS-PAGE, followed by Western blotting as
described above. Rabbit IgG was used as a control.
Statistical analysis
These procedures were repeated three times, and
data are presented as mean ± standard deviation.
Differences among groups were determined using
analysis of variance and SNK-q test. A p value of
less than 0.05 was considered to be statistically
significant.
Results
Downregulation of S100A13 induced by
S100A13-specific shRNA
The results of sequencing of shRNA-pENTR/U6-
S100A13 entry vector demonstrated that no mu-
tation and deletion occurred in the S100A13 ds
oligo insert. Thus, the S100A13 lentiviral RNAi
entry vector was constructed successfully. The
pLenti6-GW/U6-S100A13shRNA expression con-
struct was identified using PCR, and results showed
that the U6 RNAi cassette was transferred cor-
rectly from pENTR/U6 into the pLenti6/BLOCK-
iT-DEST vector.
mRNA levels of the S100A13 gene were nor-
malized against the housekeeping gene, GAPDH.
In control cells and SR-PSOX RNAi cells, mRNA
levels of S100A13 were higher and not signifi-
cantly different from control, suggesting that the
mRNA expression of S100A13 in the HUVECs
was not inhibited by SR-PSOX shRNA (control
shRNA). By contrast, mRNA levels of S100A13
were clearly downregulated in cells transfected
with S100A13-specific lentiviral RNAi entry plas-
mid and expression plasmid. When compared with
control and SR-PSOX RNAi cells, the inhibition
efficiency reached approximately 90% (Figure 1).
These results suggested that the specific shRNA
lentiviral entry and expression vector of the
S100A13 gene can specifically and efficiently in-
hibit the mRNA expression of the S100A13 gene
in HUVECs.
To further test the inhibitory efficiency of 
the vectors on protein expression of S100A13 
in HUVECs, Western blotting was performed. 
As shown in Figure 2, the high expression level
of S100A13 protein was detected in the control
and SR-PSOX RNAi cells, while the expression of
S100A13 protein was downregulated in the two
S100A13 RNAi groups. After normalization against
β-actin, the protein level of S100A13 in cells
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Figure 1. Expression for S100A13 mRNA after S100A13
RNAi knockdown. Normalized S100A13 mRNA expressions
are summarized in the bar chart. Control cell=normal human
umbilical vein endothelial cells (HUVEC); SR-PSOX-RNAi =
SR-PSOX shRNAi transfected cells; S100A13-RNAi 1 =
HUVEC transfected with S100A13 entry vector; S100A13-
RNAi 2 = HUVEC transfected with S100A13 expression
vector.
transfected with S100A13-specifc shRNA lentivi-
ral entry and expression vectors was inhibited
with an efficiency of approximately 90%. Our re-
sults suggest that the protein level of S100A13 in
the HUVECs was not affected by the SR-PSOX
RNAi, but inhibited specifically and efficiently
by the specific shRNA lentiviral entry and expres-
sion vector for the S100A13 gene.
Immunofluorescence staining was also used to
determine protein expression of S100A13 (Figure
3). Results showed that S100A13 protein was ex-
pressed mainly in the cytoplasm and perinuclear
area of the HUVECs, and expression was dramat-
ically inhibited by lentiviral RNAi entry and ex-
pression vectors for the S100A13 gene, but no
impact was observed using SR-PSOX RNAi.
Serum-deprivation induced release of FGF-1
was blocked by S100A13 gene silencing
It was revealed that FGF-1 was evenly distributed
in the cytoplasm, especially in the perinuclear 
region (Figure 4A), and S100A13 RNAi did not
affect this distribution (Figure 4B). After cells were
serum-deprived, FGF-1 was distributed mostly ad-
jacent to the cell membrane but not the perinu-
clear region, and the protein level of FGF-1 in
cells was evidently decreased compared with the
untreated cells (Figure 4C). Cells treated with
S100A13 RNAi and serum-deprivation, FGF-1 pro-
tein was similarly redistributed, from a diffuse
cytosolic pattern to an area near the inner surface
of the plasma membrane, but protein level in cells
was not significantly changed compared with con-
trol cells (Figure 4D). We further collected the cell
culture medium of the four groups to perform
ELISA (Table and Figure 5). The protein concen-
tration of FGF-1 in cell medium in control and
S100A13 RNAi cells was very low, while in cells
deprived of serum, FGF-1 was obviously increased.
When S100A13 gene was downregulated by RNAi,
the serum-deprivation induced release of FGF-1
was blocked, and the protein concentration of
FGF-1 in the cell medium was very low and almost
equal to the control and S100A13 RNAi cells. 
To uncover the mechanism underlying S100A13
Figure 2. Expression of S100A13 protein after S100A13
RNAi knockdown. Control cell = normal human umbilical
vein endothelial cells (HUVEC); SR-PSOX-RNAi = SR-PSOX
shRNAi transfected cells; S100A13-RNAi 1 = HUVEC trans-
fected with S100A13 entry vector; S100A13-RNAi 2 =
HUVEC transfected with S100A13 expression vector.
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knockdown induced block of FGF-1 release from
the cellular membrane, co-immunoprecipitation
between S100A13 and FGF-1 was performed in
HUVECs infected with S100A13 RNAi and SR-
PSOX RNAi lentivirus, respectively. As shown in
Figure 6, no physical interaction was observed be-
tween S100A13 and FGF-1 in both S100A13 RNAi
and SR-PSOX RNAi lentivirus infected HUVECs.
These results suggested that S100A13 gene silencing
did not affect the redistribution of FGF-1 protein,
but may have blocked serum-deprivation induced
FGF-1 release from the plasma membrane.
Discussion
The S100 protein family is the largest protein su-
perfamily with an EF-hand domain. This family is
involved in many biological processes, including
the cell cycle, cell differentiation and oncogenesis,
through their regulation of the interaction with
Ca2+ and a target protein.12–14 Many members of
the S100 family have abnormal expression in tu-
mors and are involved in the metastasis of tumors.
S100A4, S100A6, S100A7 and S100B, for example,
are overexpressed in a variety of tumors and are
associated with an increase in malignant tumor
cells and tumor metastasis.15 S100A13 is a new
member of the S100 gene family, but its exact role
in many biological activities remains to be deter-
mined. Specifically, the function of S100A13 in the
non-classical (non-vesicular) release route of FGF-1
is currently being investigated. FGF-1, as a potent
mitogen and angiogenic protein, has attracted in-
creasing attention as a participant in the initia-
tion, development and metastasis of tumors.16–18
A B
C D
Figure 3. Immunofluorescence staining of S100A13 protein after S100A13 RNAi knockdown. (A) Control human umbil-
ical vein endothelial cells (HUVEC); (B) SR-PSOX shRNAi transfected HUVEC cells; (C) HUVEC transfected with S100A13
entry vector; and (D) HUVEC transfected with S100A13 expression vector.
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Table. Protein concentration of FGF-1 in culture medium of human umbilical vein endothelial cells (HUVEC)
Normal S100A13 RNAi Serum-deprived Serum-deprived S100A13 
HUVEC transfected HUVEC HUVEC RNAi transfected HUVEC
Concentration (pg/mL) 26.97 ± 2.39 28.98 ± 1.79 121.79 ± 5.42 26.87 ± 2.71
A B
C D
Figure 4. Immunofluorescence staining of FGF-1 subjected to serum deprivation for 3 hours. (A) Normal human umbilical
vein endothelial cells (HUVEC); (B) S100A13 RNAi transfected HUVEC; (C) Serum-deprived HUVEC; and (D) Serum-
deprived S100A13 RNAi transfected HUVEC.
To produce a biological effect, FGF-1 needs to 
be released from cells. FGF-1 lacks conventional
signal sequencing in the amino terminal, and is
therefore released via the ER-Golgi-independent
non-classical route, which requires the association
of FGF-1 with S100A13 and p40Syt-1.19,20 This
observation implies that RNAi targeted at the
S100A13 gene can block the release of FGF-1,
thus inhibit the development of tumors and the
angiogenesis in tumors.
RNAi, a sequence-specific post-transcriptional
silencer mediated by dsRNA, is an important pro-
tective mechanism against transposon and virus
transfection, and also a means for regulating the
expression of endogenous genes in the process of
growth and development.21 As a simple and effec-
tive alternative for the gene knockout technique,
RNAi has been widely used in experimental re-
search and clinical practice. In this study, we used
lentiviral vector mediated shRNA to suppress the
expression of the S100A13 gene. The whole
S100A13 gene was analyzed with specialized design
software for shRNA, and gene 215–235bp was
selected as our intervention target. 42.86% in
G/C, CAAC (5’ end), AAAA (3’ end), CGAA hair-
pin loop and TTCG antisense hairpin loop were
Downregulation of S100A13 blocks FGF-1 release
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added to the two complementary single-stranded
shRNA for cloning. The pENTR/U6 entry vector
provided a rapid and efficient way to add dsDNA
into a vector containing a RNA PolIII-dependent
expression cassette for use in RNAi analysis. Using
the Gateway technique the U6 RNAi cassette 
is easily recombined into the DEST vector, which
then generates replication-incompetent lenti-
virus to silence the target gene. After construction
of the S100A13 shRNA expression vector, the 
interference effect on the S100A13 gene was 
observed using RT-PCR, Western blotting and
immunofluorescence staining. The results sug-
gested both the entry vector and the expression
vector of the S100A13-shRNA could downregu-
late the expression of S100A13, with an interfer-
ence efficiency of 90%. The construction of this
S100A13-shRNA lentiviral vector is essential for
the further investigation into the biological effects
of S100A13.
Maciag et al first demonstrated that S100A13
and p40 synaptotagmin-1 can be co-purified from
brain homogenates with FGF-1, and further dem-
onstrated that heat shock stress causes a co-
release of FGF-1, S100A13 and Syt-1 from NIH3T3
cells.19,20 In the present study we attempted to ex-
amine the effect of the S100A13 gene on serum
deprivation induced release of FGF-1 by the
shRNA silencing of the S100A13 gene. Our re-
sults suggested that FGF-1 was expressed in en-
dothelium cells in normal culture condition, and
is diffusely distributed in the cytosol, which is
consistent with other studies.22 Under normal con-
ditions, cells do not release FGF-1 protein. Several
stresses, however, such as heat shock, serum star-
vation, hypoxia and low-density lipoprotein treat-
ment, can induce the release of FGF-1.23 Our study
demonstrated a change in location of FGF-1 fol-
lowing serum deprivation with FGF-1 mostly lo-
calizing in the inner surface of the cell membrane,
and not the perinuclear region of the cytosol.
Furthermore, FGF-1 almost disappeared from the
cells after the endothelium was subjected to serum
deprivation stress. Some researchers have suggested
that FGF-1 is connected with S100A13, p40Syt-1
and Cu2+ to form multiprotein release complexes,
which allows the transport of FGF-1 to the cell
medium.24 Although biochemical evidence sug-
gests that the formation of a multiprotein release
complex containing S100A13 and p40Syt-1 is
important for the release of FGF-1, the role of the
S100A13 gene in the process of FGF-1 release 
is still unclear. We attempted to determine the
involvement of S100A13 in serum-deprivation
induced FGF-1 release through silencing the ex-
pression of the S100A13 gene by using specific
S100A13 shRNA. We observed that S100A13 RNAi
did not affect the expression and distribution of
FGF-1 in the control and serum-deprived cells, but
blocked serum-deprivation induced FGF-1 release
from the inner surface of the plasma membrane
to the cell medium. Co-immunoprecipitation re-
sults showed that no interaction occurred between
S100A13 and FGF-1 in HUVECs, indicating an
indirect manner by which S100A13 functions as
a cargo protein of FGF-1. These findings suggest
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Figure 5. Enzyme linked immunosorbent assay of the
FGF-1 protein in culture medium. (A) Normal human um-
bilical vein endothelial cells (HUVEC); (B) S100A13 RNAi
transfected HUVEC; (C) Serum-deprived HUVEC; and 
(D) Serum-deprived S100A13 RNAi transfected HUVEC.
WB S100A13
FGF-1
S100A13
FGF-1
WB
IgG FGF-1 S100A13 IgG FGF-1 S100A13
PSOX-RNAi A13-RNAi 2
IP: IP:
Figure 6. Co-immunoprecipitation of S100A13 and FGF-1
in human umbilical vein endothelial cells. IgG was used as
a control. IP = Immunoprecipitation; WB = Western blot.
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that S100A13 RNAi may block the release process
for FGF-1. S100A13 may be a key cargo protein in
the final export mechanism in the non-classical
release of FGF-1 during serum-deprivation stress.
Further functional studies investigating the mech-
anisms involved, and the role of S100A13 in these
processes, are needed.
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